U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831772) titled 'REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma' on Sept. 09.
Brief Summary: REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma.
Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead-in phase while receiving standard-of-care therapy off study. Approximately 4 weeks after temozolomide, participants will receive one study-specific 2 Gy fraction of maintenance radiotherapy directed at the post-operative cavity and areas of pri...